Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with a
high prevalence in females of childbearing age. Pregnancy in SLE nowadays has favorable …

Systemic lupus erythematosus (SLE) can be a severe and potentially life-threatening
disease that often represents a therapeutic challenge because of its heterogeneous organ …

Anti-Jo-1 is the most frequently detectable antibody in the antisynthetase syndrome (ASSD),
an autoimmune disease characterized by the occurrence of arthritis, myositis, and interstitial …

Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying
antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA). …

Introduction Evidence from a number of open-label, uncontrolled studies has suggested that
rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-…

Anti Jo-1 antibodies are the main markers of the antisynthetase syndrome (ASSD), an
autoimmune disease clinically characterized by the occurrence of arthritis, myositis, and interstitial …

Increased in vitro apoptosis and altered expression of apoptosis-related molecules have
been reported in systemic lupus erythematosus (SLE). It was speculated that autoantigens …

Introduction Whether patients with inflammatory rheumatic and musculoskeletal diseases (RMD)
are at higher risk to develop severe courses of COVID-19 has not been fully elucidated. …

Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the
occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung …

Aim To determine characteristics associated with more severe outcomes in a global registry
of people with systemic lupus erythematosus (SLE) and COVID-19. Methods People with …